The current study presented that plasma leptin levels were significantly higher in MS patients as compared to the healthy control subjects, which confirms that it could be recognized as a pro-inflammatory cytokine affecting immune response in MS and indicate this protein as a potential circulating marker useful in disease diagnosis. This evidence concerns the gene LEP and myeloid sarcoma.